Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (259)	12/16/2000 10:40:04 PM
From: scaram(o)uche	Respond to of 1784

The R&D Systems catalog always came out with those superb mini-reviews. Presume that they're still doing it. The company was always known for quality, and I used to spend and spend and spend and spend with them. Recommended TECH -- as a trickle play during a mini-sector rally -- in an article for Microsoft Investor a few years ago.

To: Pseudo Biologist who wrote (259)	12/17/2000 3:07:13 AM
From: tuck	Read Replies (1) \| Respond to of 1784

PB, >>Cytokine Mini-Reviews? Chemistry? Basic immunology more like it<< I love this job. I get to prove my ignorance every day. I'm slightly better at instrumentation. So let's see. Does that mean you'd spend more at TECH and td would spend more at SIAL? That is, TECH's products are targeted more at biologists/immunologists than medicinal chemists? How about QGENF? I heard somewhere biologists want everything done for them. Does TECH do that? Cheers, Tuck